Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common stock, par value $0.001 per share
-
Shares outstanding
-
5,434,244
-
Total 13F shares
-
4,999,711
-
Share change
-
-1,538,297
-
Total reported value
-
$25,549,281
-
Put/Call ratio
-
347%
-
Price per share
-
$5.11
-
Number of holders
-
37
-
Value change
-
-$7,565,851
-
Number of buys
-
17
-
Number of sells
-
25
Institutional Holders of Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) as of Q3 2021
As of 30 Sep 2021,
Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) was held by
37 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,999,711 shares.
The largest 10 holders included
Versant Venture Management, LLC, VANGUARD GROUP INC, Redmile Group, LLC, BlackRock Inc., KENNEDY CAPITAL MANAGEMENT, INC., SUSQUEHANNA INTERNATIONAL GROUP, LLP, GEODE CAPITAL MANAGEMENT, LLC, JPMORGAN CHASE & CO, MORGAN STANLEY, and GOLDMAN SACHS GROUP INC.
This page lists
37
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.